- Excerpt
As a result of the need for changes, Masquelier filed another French Patent for an improved production method on December 14, 1964, describing the making of OPCs from the bark of the Maritime Pine.
[…..]
In the 17 years that separated the first from the third French Patent, Masquelier and his colleagues had delved deeper into the nature of leucocyanidin. They had found that leucocyanidin was not one single substance but that there existed a series of consecutive complex forms of leucocyanidins in degrees of condensation ranging from two units to 5, 10 or more. Not yet knowing the precise details and mechanisms of this condensation,
[…..]
In the 1965 patent, Masquelier lists an impressive range of vascular conditions that respond well to Flavan:
• Capillary fragility
• Tendency to ecchymosis (hematoma or “blue spots” occurring spontaneously or after bruising or sports injuries)
• Vascular problems in those with high blood pressure
• Diabetic retinopathy (eyesight problems due to impaired circulation of the retina in diabetics)
• Capillary fragility caused by renal insufficiency, hepatic insufficiency, or infectious diseases
• Abnormally high capillary permeability
• Swollen legs, “heavy legs”
• Varicose conditions, varicose ulcers
• Sequels of phlebitis (vein inflammation)
• Edema in premature infants
• Edema caused by hepatic insufficiency
• Pleural cardiac effusion
• Pleurisy
• Periarthritis
• Allergic reactions (urticaria, eczema, Quincke’s edema, dishidrosis)
• Dermatoses (pemphigus – “water blisters”, psoriasis)
• Cellulitis
[…..]
The improvement of capillary resistance expresses itself in all kinds of conditions caused by venolymphatic weakness, such as heavy legs, cramps, pain, tingling and numbness of extremities (paresthesia), edema, capillary fragility of the skin (including bruises and teleangiectatic rosacea/“spider veins”), hematoma (ecchymosis), eye troubles, circulatory disorder of the retina and choroid (see chapter 19: New Clinical Highlights), and hemorrhoid prolapse.
[…..]
A Flavan study conducted by ophthalmologists with patients suffering from conjunctivitis, macular degeneration, retinopathy, and lesions ends with a recommendation by Bessiere: “The medication appears especially effective when the lesion is moderate and if prolonged treatment can be prescribed. We must stress the favorable effect of Flavan in conditions of doubtful prognosis in spite of conventional therapy. In particular, the comparison with other vitamin P factors hitherto used is very much in the product’s favor.”
“In addition to certain beneficial physiological properties currently under study (modification of electrogenesis and visual acuity curve in low luminosity), we consider Flavan, of all the vitamin factors currently available, to have the most intense and reliable action on disorders affecting capillary resistance and permeability.”
